FDA Allays Pradaxa Concerns

by Kathy Jones on  November 3, 2012 at 5:14 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

The US Food and Drug Administration declared that the risk of bleeding in patients who are new to Boehringer Ingelheim's blood-clot preventer Pradaxa is not higher than the currently used blood thinner warfarin.
 FDA Allays Pradaxa Concerns
FDA Allays Pradaxa Concerns

The FDA had earlier approved Ingelheim's Pradaxa for preventing strokes in patients who suffer from atrial fibrillation but safety concerns over the pill emerged following reports that it posed a risk for bleeding in patients who were newly introduced to the drug.

The FDA hopes that this announcement will allay any safety concerns over the pill.

The FDA compared the insurance claims and electronic health data of both warfarin and Pradaxa users from October 2010 to December 2011 and found that instances of intracranial and gastrointestinal hemorrhage in patients taking warfarin was 1.8 to 2.6 times higher compared to Pradaxa. "The results indicate that the observed bleeding rates associated with new use of Pradaxa do not appear to be higher than the bleeding rates associated with new use of warfarin", he FDA said.


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive